Jiyoun Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9009641/publications.pdf

Version: 2024-02-01

74	2,230	218677	243625
papers	citations	26 h-index	44 g-index

79	79	79	3215
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The translocator protein ligands as mitochondrial functional modulators for the potential anti-Alzheimer agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 831-846.	5.2	10
2	Recent Advances in Organelle-Targeted Fluorescent Probes. Molecules, 2021, 26, 217.	3.8	43
3	Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design. European Journal of Medicinal Chemistry, 2021, 226, 113819.	5.5	7
4	Mitochondrion-Targeting Peptides and Peptidomimetics: Recent Progress and Design Principles. Biochemistry, 2020, 59, 270-284.	2.5	37
5	Activity-Based Probes for the High Temperature Requirement A Serine Proteases. ACS Chemical Biology, 2020, 15, 2346-2354.	3.4	7
6	Helicity Modulation Improves the Selectivity of Antimicrobial Peptoids. ACS Infectious Diseases, 2020, 6, 2732-2744.	3.8	25
7	Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention. BMB Reports, 2020, 53, 47-55.	2.4	17
8	Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimerâ€™s Agents by Structure-Based Design. Journal of Medicinal Chemistry, 2019, 62, 8011-8027.	6.4	16
9	Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1). Bioorganic and Medicinal Chemistry, 2019, 27, 1099-1109.	3.0	6
10	Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 3133-3144.	3.0	16
11	Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimerâ€™s agents: Structure-activity relationship study of Arg-mimetic region. Bioorganic and Medicinal Chemistry, 2018, 26, 1035-1049.	3.0	19
12	Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. European Journal of Medicinal Chemistry, 2018, 145, 413-424.	5.5	5
13	A Turnâ€On Fluorescent Probe for Liveâ€Cell Imaging of Biothiols. Bulletin of the Korean Chemical Society, 2018, 39, 425-426.	1.9	4
14	Mitochondria-Targeting Peptoids. Bioconjugate Chemistry, 2018, 29, 1669-1676.	3.6	26
15	Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aî²-induced mitochondrial dysfunction in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 144, 529-543.	5.5	25
16	Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 170-173.	2.2	41
17	Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a Î²-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 396-402.	6.4	30
18	Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aî²-induced mPTP opening for Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 157, 268-278.	5.5	10

#	Article	IF	Citations
19	Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 4073-4079.	3.0	11
20	Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimerâ€™s Agents Based on Rational Design. Journal of Medicinal Chemistry, 2017, 60, 2573-2590.	6.4	33
21	Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2 H)-ones: A novel class of TSPO ligands modulating amyloid-Î²-induced mPTP opening. European Journal of Pharmaceutical Sciences, 2017, 104, 366-381.	4.0	23
22	Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4145-4152.	3.0	16
23	Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction. European Journal of Medicinal Chemistry, 2017, 128, 56-69.	5.5	26
24	Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-Î²-induced toxicity. European Journal of Medicinal Chemistry, 2017, 141, 322-334.	5.5	19
25	Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against AÎ²-induced neurotoxicity. European Journal of Medicinal Chemistry, 2017, 141, 240-256.	5.5	6
26	Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in AÎ²-induced mitochondrial dysfunction. Journal of Computer-Aided Molecular Design, 2017, 31, 929-941.	2.9	19
27	Development of a smart activity-based probe to detect subcellular activity of asparaginyl endopeptidase in living cells. Organic and Biomolecular Chemistry, 2017, 15, 8018-8022.	2.8	13
28	Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 125, 1172-1192.	5.5	26
29	Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3038-3041.	2.2	16
30	Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Medicinal Chemistry, 2016, 59, 9150-9172.	6.4	15
31	A 1,8-naphthalimide-based chemosensor for dual-mode sensing: colorimetric and fluorometric detection of multiple analytes. RSC Advances, 2016, 6, 84098-84105.	3.6	27
32	Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10322-10328.	6.4	15
33	Mitochondrial drug targets in neurodegenerative diseases. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 714-720.	2.2	23
34	Discovery of a Small Molecule that Enhances Astrocytogenesis by Activation of STAT3, SMAD1/5/8, and ERK1/2 via Induction of Cytokines in Neural Stem Cells. ACS Chemical Neuroscience, 2016, 7, 90-99.	3.5	16
35	Thiopheneâ€substituted Azaâ€<scp>BODIPY</scp>s as Nearâ€Infrared Fluorophores. Bulletin of the Korean Chemical Society, 2015, 36, 1747-1748.	1.9	1
36	Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain. European Journal of Medicinal Chemistry, 2015, 97, 245-258.	5.5	13

#	Article	IF	Citations
37	Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: A potential treatment for neuropathic pain. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1324-1328.	2.2	7
38	6-Phenoxy-2-phenylbenzoxazoles, novel inhibitors of receptor for advanced glycation end products (RAGE). Bioorganic and Medicinal Chemistry, 2015, 23, 4919-4935.	3.0	11
39	Prostate tumor specific peptideâ€“peptoid hybrid prodrugs. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2849-2852.	2.2	17
40	Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists. Bioorganic and Medicinal Chemistry, 2015, 23, 7717-7727.	3.0	12
41	Novel quinazoline-urea analogues as modulators for AÎ²-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study. European Journal of Medicinal Chemistry, 2014, 84, 466-475.	5.5	30
42	Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity. European Journal of Medicinal Chemistry, 2013, 63, 558-569.	5.5	20
43	Target deconvolution techniques in modern phenotypic profiling. Current Opinion in Chemical Biology, 2013, 17, 118-126.	6.1	137
44	Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy. Journal of Medicinal Chemistry, 2013, 56, 9008-9018.	6.4	40
45	Aminopropyl carbazole analogues as potent enhancers of neurogenesis. Bioorganic and Medicinal Chemistry, 2013, 21, 7165-7174.	3.0	30
46	Functional Imaging of Legumain in Cancer Using a New Quenched Activity-Based Probe. Journal of the American Chemical Society, 2013, 135, 174-182.	13.7	131
47	The Selective A3AR Antagonist LJ-1888 Ameliorates UUO-Induced Tubulointerstitial Fibrosis. American Journal of Pathology, 2013, 183, 1488-1497.	3.8	39
48	Porphyrinâ€“Peptoid Conjugates: Face-to-Face Display of Porphyrins on Peptoid Helices. Organic Letters, 2013, 15, 1670-1673.	4.6	28
49	Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction. European Journal of Medicinal Chemistry, 2013, 62, 71-83.	5.5	15
50	Coupling Protein Engineering with Probe Design To Inhibit and Image Matrix Metalloproteinases with Controlled Specificity. Journal of the American Chemical Society, 2013, 135, 9139-9148.	13.7	35
51	Structureâ€“activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorganic and Medicinal Chemistry, 2013, 21, 3821-3830.	3.0	33
52	The SAR analysis of TRPV1 agonists with the Î±-methylated B-region. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5227-5231.	2.2	5
53	Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1340-1343.	2.2	28
54	Pyridyl-urea Derivatives as Blockers of AÎ²-induced mPTP Opening for Alzheimer's Disease. Bulletin of the Korean Chemical Society, 2012, 33, 3887-3888.	1.9	3

#	Article	IF	Citations
55	Cobalt (III) Complexes as Novel Matrix Metalloproteinase-9 Inhibitors. Bulletin of the Korean Chemical Society, 2012, 33, 2762-2764.	1.9	3
56	Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. Journal of Experimental Medicine, 2011, 208, 643-651.	8.5	276
57	Development of Near-Infrared Fluorophore (NIRF)-Labeled Activity-Based Probes for in Vivo Imaging of Legumain. ACS Chemical Biology, 2010, 5, 233-243.	3.4	75
58	Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13667-13672.	7.1	80
59	Rational Design, Synthesis, and Biological Evaluation of Progesterone-Modified MRI Contrast Agents. Chemistry and Biology, 2007, 14, 824-834.	6.0	35
60	Analysis of structureâ€“activity relationships for the â€˜B-regionâ€™ of N-(4-t-butylbenzyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4143-4150.	2.2	14
61	A Steroid-Conjugated Contrast Agent for Magnetic Resonance Imaging of Cell Signaling. Journal of the American Chemical Society, 2005, 127, 13164-13166.	13.7	45
62	Analysis of structureâ€“activity relationships for the â€˜B-regionâ€™ of N -(3-acyloxy-2-benzylpropyl)- N â€² -[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N -hydroxythiourea analogue with potent analgesic activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2291-2297.	2.2	13
63	Structureâ€“activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding. Bioorganic and Medicinal Chemistry, 2004, 12, 1055-1069.	3.0	9
64	Analysis of structureâ€“activity relationships with the N-(3-acyloxy-2-benzylpropyl)-Nâ€²-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism. Bioorganic and Medicinal Chemistry, 2004, 12, 3411-3420.	3.0	14
65	N-4-Substituted-benzyl-Nâ€²-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 787-791.	2.2	29
66	N-(3-Acyloxy-2-benzylpropyl)-Nâ€˜-[4-(methylsulfonylamino)benzyl]thiourea Analogues:Â Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor. Journal of Medicinal Chemistry, 2003, 46, 3116-3126.	6.4	110
67	High-Affinity Partial Agonists of the Vanilloid Receptor. Molecular Pharmacology, 2003, 64, 325-333.	2.3	38
68	High Affinity Antagonists of the Vanilloid Receptor. Molecular Pharmacology, 2002, 62, 947-956.	2.3	97
69	Phenolic Modification as an Approach to Improve the Pharmacology of the 3-Acyloxy-2-benzylpropyl Homovanillic Amides and Thioureas, a Promising Class of Vanilloid Receptor Agonists and Analgesics. Bioorganic and Medicinal Chemistry, 2002, 10, 1171-1179.	3.0	14
70	N-(3-acyloxy-2-benzylpropyl)-Nâ€²-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics. Bioorganic and Medicinal Chemistry, 2001, 9, 19-32.	3.0	49
71	N-(3-Acyloxy-2-Benzylpropyl)-Nâ€²-Dihydroxytetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1713-1720.	3.0	22
72	3-Acyloxy-2-phenalkylpropyl amides and esters of homovanillic acid as novel vanilloid receptor agonists. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2909-2914.	2.2	17

#	Article	IF	Citations
73	A Facile and Practical Synthesis of Capsazepine, a Vanilloid Receptor Antagonist. Synthetic Communications, 1999, 29, 4127-4140.	2.1	6
74	Synthesis and structureâ€activity relationship of mitochondriaâ€targeting peptoids with varying hydrophobicity and cationic charge. Peptide Science, 0, , e24239.	1.8	1